or.47. characterization of foxp3+cd4+cd25+ regulatory t‐cells from mesenteric lymph nodes in human...

1
CD4+CD25À regulatory T-cells (T R ) have emerged as potent regulators of immune responses. The ability to generate and expand antigen-specific T R may provide targeted immunotherapy for autoimmune diseases and transplant. In a previous report, we have shown that activation of human CD4+CD25À results in expression of FoxP3 and CD25, as well as, acquisition of a cell contact dependent, cytokine independent regulatory activity by a portion of the original CD4+CD25À T-cells. These T R can be generated by activation on peptide antigen and subse- quently behave in an antigen-specific manner. First, we induced CD4+CD25À T-cells to become regulatory with a foreign peptide, Hemaglutanin, HA (306-319), however, recently we have induced T R with a diabetes autoantigen, GAD65 (555-567). In both systems selection of antigen- specific regulatory T-cells is dependent on MHC class II tetramers. Antigen activation of CD4+CD25À cells results in two populations of cells that are CD25, Tetramer+ and TetramerÀ , with only the Tetramer cells suppressing antigen-specifically. These induced T R behave antigen- specifically in that they need to be activated on cognate antigen in order to be suppressive, but once activated they are antigen nonspecific. Thus, suggesting that antigen- specific T R may be able to control the response to unidentified autoantigens once activated on a known autoantigen. The mechanism by which these cells suppress is unknown, however it does not appear that responder cells undergo cytolysis. Notably, GAD-specific T R can be generated from both normal and diabetic subjects. Recent results show that these cells can be expanded at least 50- fold and retain suppressive ability, suggesting that these cells have the potential to be useful therapeutically. Supported by NIH grant DK072457, The Irvington Institute and Dana Foundation for Immunological Research, and The Juvenile Diabetes Research Foundation. doi:10.1016/j.clim.2006.04.201 OR.46. Comparative Analysis of FOXP3 in Target Organ and Circulation of Rheumatic Patients. Duojia Cao, 1 Sukanya Raghavan, 1 Mona Widhe, 1 Ann-Kristin Ulfgren, 1 Giovanna Roncador, 2 Alison Banham, 3 Vivianne Malmstrom, 1 Tina Trollmo. 11 Unit of Rheumatology, Karolinska Institutet, Stockholm, Sweden; 2 Biotechnology program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain; 3 Dept. of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom. FOXP3 is still the only specific marker for natural regulatory T-cells and in a naive host it correlates with the level of expression of surface-bound CD25, however in an antigen experienced host both activated and regulatory T-cells express CD25. In this study rheumatic patients with chronic joint inflammation were recruited, and both the inflamed site and peripheral blood were analyzed. Our data using flow cytometry and RT PCR demonstrated that FOXP3 expression was most abundant in the CD25brightCD4+ population independent of site of sam- pling. Interestingly, joint fluid derived CD25-CD4 T-cells expressed low but distinct FOXP3+ levels as compared to their counterpart in circulation. We also detected FOXP3+ cells in the synovial tissue of patients with rheumatic disease using immunohistochemistry and a monoclonal antibody against scurfin. The FOXP3+ cells were found mainly in T-cell rich areas of the tissue and were confined not only to CD25+ but were also found among CD25À T- cells, indicating that at a chronically active site of inflam- mation CD25 could be down regulated on the natural regu- latory T-cells, alternatively FOXP3+CD25À cells exist. In conclusion, at the site of inflammation in patients with rheumatic disease, FOXP3+ regulatory T-cells exist both in the inflamed joint fluid and tissue. Also, the new method allows frequency determinations of such cells during the different phases of disease progression and in response to treatments. doi:10.1016/j.clim.2006.04.202 OR.47. Characterization of FOXP3+CD4+CD25+ Regulatory T-Cells from Mesenteric Lymph Nodes in Human Ulcerative Colitis (UC). Konstantinos Papadakis, 1 Masayuki Saruta, 1 Qi Yu, 1 Alison Banham. 21 Gastroenterology, Cedars-Sinai Medical Center/ UCLA, Los Angeles, CA; 2 Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, United Kingdom. Background and Aims: Treg cells are able to control the development of experimental colitis. The aim of our study was to determine the presence and functional character- istics of Treg cells isolated from Mesenteric lymph nodes (MLN) in human UC. Results: MLN from human UC colon contain a subset of CD4+CD25+ T-cells with phenotypic characteristics of Treg cells (expression of CCR4, CD122, HLA-DR, GITR and intracellular CTLA4). FoxP3+ Cells were detected by IHC in the MLN medulla dispersed in the T-cell rich areas and occasionally in the follicles. CD4+CD25+ cells express FoxP3 mRNA and protein and potently suppress the proliferation of autologous MLN CD4+ T-cells. In contrast to peripheral blood Treg from healthy donors, the CD4+CD25hi and CD4+CD25int MLN T-cell subsets exhibit potent sup- pressor activity in vitro. The suppressor function of CD4+CD25+FoxP3+ cells is not mediated through TGF-beta or IL-10, whereas addition of exogenous IL-2 restores the proliferation of responder CD4+ MLN T-cells. In addition to their ability to suppress the proliferation of CD4+CD25À cells, CD4+CD25+ cells potently suppressed the secretion of IL-2, IL-5, IL-13 and IFN-g by CD4+CD25À effector T-cells. Conclusions: CD4+CD25+ T-cells isolated from human co- lonic MLN in UC display typical features of Treg cells and possess potent suppressor activity in vitro in spite of persistent mucosal inflammation. These data suggest that their suppressor activity is likely compromised in vivo and finding ways to restore their suppressive activity is desirable in order to achieve long-term tolerance in the gut. doi:10.1016/j.clim.2006.04.203 Abstracts S21

Upload: konstantinos-papadakis

Post on 05-Sep-2016

214 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: OR.47. Characterization of Foxp3+Cd4+Cd25+ Regulatory T‐Cells from Mesenteric Lymph Nodes in Human Ulcerative Colitis (UC)

CD4+CD25� regulatory T-cells (TR) have emerged aspotent regulators of immune responses. The ability togenerate and expand antigen-specific TR may providetargeted immunotherapy for autoimmune diseases andtransplant. In a previous report, we have shown thatactivation of human CD4+CD25� results in expression ofFoxP3 and CD25, as well as, acquisition of a cell contactdependent, cytokine independent regulatory activity by aportion of the original CD4+CD25� T-cells. These TR can begenerated by activation on peptide antigen and subse-quently behave in an antigen-specific manner. First, weinduced CD4+CD25� T-cells to become regulatory with aforeign peptide, Hemaglutanin, HA (306-319), however,recently we have induced TR with a diabetes autoantigen,GAD65 (555-567). In both systems selection of antigen-specific regulatory T-cells is dependent on MHC class IItetramers. Antigen activation of CD4+CD25� cells results intwo populations of cells that are CD25, Tetramer+ andTetramer�, with only the Tetramer cells suppressingantigen-specifically. These induced TR behave antigen-specifically in that they need to be activated on cognateantigen in order to be suppressive, but once activated theyare antigen nonspecific. Thus, suggesting that antigen-specific TR may be able to control the response tounidentified autoantigens once activated on a knownautoantigen. The mechanism by which these cells suppressis unknown, however it does not appear that respondercells undergo cytolysis. Notably, GAD-specific TR can begenerated from both normal and diabetic subjects. Recentresults show that these cells can be expanded at least 50-fold and retain suppressive ability, suggesting that thesecells have the potential to be useful therapeutically.Supported by NIH grant DK072457, The Irvington Instituteand Dana Foundation for Immunological Research, and TheJuvenile Diabetes Research Foundation.

doi:10.1016/j.clim.2006.04.201

OR.46. Comparative Analysis of FOXP3 in TargetOrgan and Circulation of Rheumatic Patients.Duojia Cao,1 Sukanya Raghavan,1 Mona Widhe,1

Ann-Kristin Ulfgren,1 Giovanna Roncador,2 Alison Banham,3

Vivianne Malmstrom,1 Tina Trollmo.1 1Unit ofRheumatology, Karolinska Institutet, Stockholm, Sweden;2Biotechnology program, Centro Nacional deInvestigaciones Oncologicas, Madrid, Spain; 3Dept. ofClinical Laboratory Sciences, John Radcliffe Hospital,Oxford, United Kingdom.

FOXP3 is still the only specific marker for naturalregulatory T-cells and in a naive host it correlates withthe level of expression of surface-bound CD25, however inan antigen experienced host both activated and regulatoryT-cells express CD25. In this study rheumatic patients withchronic joint inflammation were recruited, and both theinflamed site and peripheral blood were analyzed.Our data using flow cytometry and RT PCR demonstratedthat FOXP3 expression was most abundant in theCD25brightCD4+ population independent of site of sam-pling. Interestingly, joint fluid derived CD25-CD4 T-cells

expressed low but distinct FOXP3+ levels as compared totheir counterpart in circulation. We also detected FOXP3+cells in the synovial tissue of patients with rheumaticdisease using immunohistochemistry and a monoclonalantibody against scurfin. The FOXP3+ cells were foundmainly in T-cell rich areas of the tissue and were confinednot only to CD25+ but were also found among CD25� T-cells, indicating that at a chronically active site of inflam-mation CD25 could be down regulated on the natural regu-latory T-cells, alternatively FOXP3+CD25� cells exist. Inconclusion, at the site of inflammation in patients withrheumatic disease, FOXP3+ regulatory T-cells exist both inthe inflamed joint fluid and tissue. Also, the new methodallows frequency determinations of such cells during thedifferent phases of disease progression and in response totreatments.

doi:10.1016/j.clim.2006.04.202

OR.47. Characterization of FOXP3+CD4+CD25+Regulatory T-Cells from Mesenteric Lymph Nodes inHuman Ulcerative Colitis (UC).Konstantinos Papadakis,1 Masayuki Saruta,1 Qi Yu,1 AlisonBanham.2 1Gastroenterology, Cedars-Sinai Medical Center/UCLA, Los Angeles, CA; 2Nuffield Department of ClinicalLaboratory Sciences, University of Oxford, Oxford, UnitedKingdom.

Background and Aims: Treg cells are able to control thedevelopment of experimental colitis. The aim of our studywas to determine the presence and functional character-istics of Treg cells isolated from Mesenteric lymph nodes(MLN) in human UC. Results: MLN from human UC coloncontain a subset of CD4+CD25+ T-cells with phenotypiccharacteristics of Treg cells (expression of CCR4, CD122,HLA-DR, GITR and intracellular CTLA4). FoxP3+ Cells weredetected by IHC in the MLN medulla dispersed in the T-cellrich areas and occasionally in the follicles. CD4+CD25+ cellsexpress FoxP3 mRNA and protein and potently suppress theproliferation of autologous MLN CD4+ T-cells. In contrast toperipheral blood Treg from healthy donors, the CD4+CD25hiand CD4+CD25int MLN T-cell subsets exhibit potent sup-pressor activity in vitro. The suppressor function ofCD4+CD25+FoxP3+ cells is not mediated through TGF-betaor IL-10, whereas addition of exogenous IL-2 restores theproliferation of responder CD4+ MLN T-cells. In addition totheir ability to suppress the proliferation of CD4+CD25�cells, CD4+CD25+ cells potently suppressed the secretion ofIL-2, IL-5, IL-13 and IFN-g by CD4+CD25� effector T-cells.Conclusions: CD4+CD25+ T-cells isolated from human co-lonic MLN in UC display typical features of Treg cells andpossess potent suppressor activity in vitro in spite ofpersistent mucosal inflammation. These data suggest thattheir suppressor activity is likely compromised in vivo andfinding ways to restore their suppressive activity isdesirable in order to achieve long-term tolerance in thegut.

doi:10.1016/j.clim.2006.04.203

Abstracts S21